A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission

* Age ≥18 years. * Diagnosis of RA as defined by the 1987-revised American College of Rheumatology (ACR)-classification and has positive rheumatoid factor (RF) test or erosion on X-ray of hands or feet. * Currently treated with adalimumab and MTX (at least 10 mg/week; orally or subcutaneously). * In remission as defined by disease activity score (DAS)28 \<2.6 for at least the past 3 months. * Concomitant disease-modifying anti-rheumatic drug (DMARD) or oral corticosteroid therapy has been stable for at least 3 months at study entry. * Female subject is either not of childbearing potential or is practicing a relevant method of birth control. * Subject is judged to be in good general health. * Subjects must be able and willing to provide written informed consent. * Subjects must be able and willing to self-administer subcutaneous (SC) injections or have a qualified person available to administer SC injections.

* Treatment with intra-articular or parenteral administration of corticosteroids in the preceding 4 weeks. * Oral prednisone or prednisone equivalent \> 10 mg/day at baseline. * Joint surgery within the preceding two months. * History of acute inflammatory joint disease other than RA. * Treatment with any investigational drug within 30 days or 5 half lives, whichever is longer prior to study entry. * Poorly controlled medical condition, which would put the subject at risk by participation in the study. * History of clinically significant hematologic, renal or liver disease. * Diagnosis of, or history suggestive of, central nervous system (CNS) demyelinating disease. * History of cancer or lymphoproliferative disease other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma or localized carcinoma of the cervix. * History of listeriosis, histoplasmosis, untreated tuberculosis (TB), persistent chronic infections, or recent active infections. * Known immune deficiency or human immunodeficiency virus (HIV). * Female who is pregnant or breast-feeding or considering becoming pregnant or breast feeding during the study.